Metastatic bone disease in breast cancer: the patient’s perspective. Semin Oncol 2001 ; 28 (suppl 11): 60 –63.Perez EA. Metastatic bone disease in breast cancer: the patient's perspective[J].Seminars in Oncology,2001,(28):60.Perez, E.A., (2001) Metastatic bone disease in breast ...
At least 70 per cent of patients with bone metastasis from breast cancer were relieved of pain by adequate roentgen therapy, the relief lasting for most of the survival time in many instances. About 25 per cent of patients had recalcification or reossification of bony lesions with roentgen ...
Purpose: We hypothesized different Overall Survival (OS) in metastatic breast cancer (MBC) after relapse vs de novo presentation. Methods: We identified women in British Columbia with MBC diagnosed between 01/2001 and 12/2009. OS from MBC was calculated for relapsed vs de novo cohorts in 3 su...
This exploratory analysis of a randomized clinical trial evaluates the association of bone metastasis count and location with survival benefit from
“We have a lot of work to do to improve survival for metastatic breast cancer,” said Dr. Linda Vahdat, director of breast cancer research at New York Presbyterian and Weill Cornell Medicine. “We understand how tumors grow, we understand how they spread, we have a lot of things that ma...
By the Numbers: Monthly Treatment Cost Not Tied to Survival in Breast Cancer In the Shadow of Big Centers, Community Oncologists Still Thrive Liposomal Irinotecan May Be Effective in Later Lines for Pancreatic Cancer FDA Drug Approvals Q2 2024 Depiction of Cancer in Movies: Not an Accurate...
Individualized care in MBC requires predictors of survival for tailored treatment. Although HD-ASCT has not resulted in improved overall survival (OS), retrospective analyses may identify patients who benefited. We reviewed records of all patients (n=96) in the bone marrow transplant registry at UCS...
Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. Smith MR, Saad F, Shore ND et al (2012) Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in...
13 Despite the bone being the most and the brain being the least-affected metastatic sites,14 the median survival of breast cancer patients ranges from 36.0 to 8.0 months, depending on the presence of bone versus brain metastases, respectively.15 Protracted intervals between diagnosis and recurrence...
Patients with bone metastases from breast cancer are with better survival than from other tumors. Recent data suggest that survival may be improved if disease is controlled by offering loco-regional treatment of the primary tumor in metastatic breast cancer. This a case report about 44 years old ...